Fundz

Cyto Dyn Inc. reported raising $1 Million in an initial SEC Form D filing, from an offering of $1 Million

PUBLIC · CYDYDec 16, 2020

Amount Raised

$1 Million

$1 Million sold, per SEC Form D (first sale Dec 16, 2020)

Round Type

Seed

VancouverBiotechnologyHealthcareHealth CareTherapeutics

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as CytoDyn that raised within 45 days of this round, from Fundz verified event records.

  • Design Therapeutics, Inc. raised $125M (Series B) on January 27, 2021.
  • SAGE Therapeutics raised $650M on January 15, 2021.
  • Zevra Therapeutics, Inc. raised $31M on January 13, 2021.
  • Werewolf Therapeutics raised $72M (Series B) on January 7, 2021.
  • Werewolf Therapeutics raised $72M on January 7, 2021.
  • Parabilis Medicines raised $23M on January 5, 2021.

Who to call at CytoDyn, and when

A new round usually means CytoDyn is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day CytoDyn raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at CytoDyn, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at CytoDyn. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

CytoDyn

Location

1111 Main Street

Vancouver, Washington, United States

About

CytoDyn is in late-stage clinical development of leronlimab, a CCR5 receptor antagonist, to be used as a platform drug for various therapeutic indications, including NASH, NASH/HIV, oncology, and HIV. The CCR5 receptor is a protein located on the surface of various cells including white blood cells, stellate cells which produce scar tissue in the liver, cells that undergo malignant transformation, and is the predominant co-receptor needed for certain strains of HIV to infect healthy T-cells. The CCR5 receptor serves as a receptor for chemical attractants called chemokines. Chemokines are the key orchestrators of leukocyte trafficking by attracting immune cells to the sites of inflammation.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment CytoDyn raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsRobert H., Chief Financial Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for CytoDyn's next move

See what Strategic adds

CytoDyn raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.